New antibody combo offers hope for hard-to-treat multiple myeloma
NCT ID NCT07210047
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This study is for people with multiple myeloma that has returned or stopped responding to prior treatments. Researchers want to see if adding a new antibody drug called HuL001 to two standard medications (lenalidomide and dexamethasone) is safe and can shrink the cancer. About 21 participants will receive HuL001 injections every two weeks along with daily lenalidomide and weekly dexamethasone, and will be closely monitored for side effects and treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA, REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Far Eastern Memorial Hospital
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.